BR112014013650A2 - "formulações de pulverização oral e seus usos" - Google Patents

"formulações de pulverização oral e seus usos"

Info

Publication number
BR112014013650A2
BR112014013650A2 BR112014013650A BR112014013650A BR112014013650A2 BR 112014013650 A2 BR112014013650 A2 BR 112014013650A2 BR 112014013650 A BR112014013650 A BR 112014013650A BR 112014013650 A BR112014013650 A BR 112014013650A BR 112014013650 A2 BR112014013650 A2 BR 112014013650A2
Authority
BR
Brazil
Prior art keywords
spray formulations
oral spray
ssris
methods
serotonin reuptake
Prior art date
Application number
BR112014013650A
Other languages
English (en)
Inventor
Bergstrom David
Opawale Foye
Original Assignee
Suda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suda Ltd filed Critical Suda Ltd
Publication of BR112014013650A2 publication Critical patent/BR112014013650A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

resumo “formulações de spray oral e métodos para administração de sildenafila”, por tratar-se a presente invenção de formulações de spray oral de sildenafila quimicamente estáveis e farmaceuticamente aceitáveis para o tratamento de doenças, tais como a hipertensão arterial pulmonar e/ou a disfunção sexual induzida por inibidores seletivos da recaptação da serotonina (isrs), onde a formulação de spay oral tem um ph de aproximadamente 1,5 até menos de 3,0. a presente invenção refere-se também a métodos para o tratamento de doenças tais como hipertensão arterial pulmonar e/ou disfunção sexual induzida por inibidores seletivos da recaptação da serotonina (isrs). 1/1
BR112014013650A 2011-12-05 2012-12-04 "formulações de pulverização oral e seus usos" BR112014013650A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566879P 2011-12-05 2011-12-05
PCT/US2012/067763 WO2013085904A1 (en) 2011-12-05 2012-12-04 Oral spray formulations and methods for administration of sildenafil

Publications (1)

Publication Number Publication Date
BR112014013650A2 true BR112014013650A2 (pt) 2017-07-04

Family

ID=47430090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013650A BR112014013650A2 (pt) 2011-12-05 2012-12-04 "formulações de pulverização oral e seus usos"

Country Status (14)

Country Link
US (1) US9186321B2 (pt)
EP (1) EP2787967B1 (pt)
JP (1) JP6047174B2 (pt)
KR (1) KR20140117360A (pt)
CN (1) CN104822368B (pt)
AU (1) AU2012347997B2 (pt)
BR (1) BR112014013650A2 (pt)
CA (1) CA2858364C (pt)
HK (1) HK1199843A1 (pt)
IL (1) IL232970A0 (pt)
RU (1) RU2611403C1 (pt)
SG (1) SG11201402938RA (pt)
WO (1) WO2013085904A1 (pt)
ZA (1) ZA201404091B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070049A1 (en) * 2013-11-08 2015-05-14 Insys Pharma, Inc. Sildenafil sublingual spray formulation
NO2723977T3 (pt) 2014-03-19 2018-03-10
CA2981615A1 (en) * 2015-04-03 2016-10-06 Insys Development Company, Inc. Sildenafil sublingual spray formulations
US10111833B2 (en) 2015-04-03 2018-10-30 Insys Development Company, Inc. Sildenafil sublingual spray formulations
BR102015020720A2 (pt) * 2015-08-27 2017-03-01 Henrique Leonardo Pereira Luis composição hidrofíilica atóxica, bioidêntica e biodegradável à base de partículas micronizadas de acido hialurônico, com propriedades mucoadesivas e carreadoras via transmucosa aglutinadas por bioengenharia a um ipde5, para tratamento de disfunção erétil, com aplicação em sistema de spray de aerossol sublingual
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии
CN109996547A (zh) * 2016-10-31 2019-07-09 苏达有限公司 粘膜活性剂递送
US20220395559A1 (en) * 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN111110633B (zh) * 2020-01-21 2022-12-02 合肥医工医药股份有限公司 一种他达拉非喷雾剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
DE19834506A1 (de) 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
AU1881600A (en) * 1998-12-23 2000-07-31 Alza Corporation Dosage forms comprising porous particles
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
EP1237538A2 (en) * 1999-11-18 2002-09-11 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
CN1277021A (zh) * 2000-06-20 2000-12-20 王建华 一种治疗阳痿病的喷雾剂药物及其制备方法
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
WO2005077374A1 (en) 2004-02-06 2005-08-25 Becton, Dickinson And Company Formulations of phosphodiesterase 5 inhibitors and methods of use
US7554270B2 (en) * 2004-05-17 2009-06-30 Tokyo Ohka Kogyo Co., Ltd. Composition for dielectric of plasma display panel, laminate for dielectric, and method for forming the dielectric
JP2008510825A (ja) * 2004-08-23 2008-04-10 マンカインド コーポレイション ホスホジエステラーゼ５型の阻害剤の肺送達
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20110034454A1 (en) * 2006-01-11 2011-02-10 Allan Paul Dishington Morpholino pyrimidine derivatives and their use in therapy
CA2659398A1 (en) * 2006-08-02 2008-02-07 Wm. Wrigley Jr. Company Oral compositions effective for the treatment of oral cavity malodor associated with the consumption of odor-causing compounds
JP5686978B2 (ja) * 2009-03-18 2015-03-18 第一三共ヘルスケア株式会社 シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器

Also Published As

Publication number Publication date
HK1199843A1 (en) 2015-07-24
IL232970A0 (en) 2014-08-31
RU2611403C1 (ru) 2017-02-21
SG11201402938RA (en) 2014-07-30
CN104822368A (zh) 2015-08-05
US9186321B2 (en) 2015-11-17
AU2012347997B2 (en) 2017-07-20
EP2787967B1 (en) 2018-10-31
CN104822368B (zh) 2019-01-11
AU2012347997A1 (en) 2014-07-03
JP6047174B2 (ja) 2016-12-21
KR20140117360A (ko) 2014-10-07
ZA201404091B (en) 2017-11-29
US20150051216A1 (en) 2015-02-19
WO2013085904A1 (en) 2013-06-13
CA2858364A1 (en) 2013-06-13
JP2015500285A (ja) 2015-01-05
EP2787967A1 (en) 2014-10-15
CA2858364C (en) 2018-07-24
NZ625922A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
BR112014013650A2 (pt) "formulações de pulverização oral e seus usos"
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
BR112014029851A2 (pt) composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
IN2014DN09434A (pt)
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
WO2011156405A3 (en) Oral spray formulations and methods for administration of sildenafil
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
AU2017312811A8 (en) Liquid naloxone spray
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
MX2013002162A (es) Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina.
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EA201270629A1 (ru) Новые полиморфные формы метил(4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил)карбамата
EA201370230A1 (ru) Новые ингибиторы rock
BR112014004447A2 (pt) bifenilcarboxamidas como inibidores de quinase rock

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US61/566,879 DE 05/12/2011, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013, POR NAO ATENDER AO DISPOSTO NO ART. 2 DA RESOLUCAO INPI-PR 179/2017, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL.

B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements